Emerging Medical Therapies for Primary Aldosteronism - PubMed
8 days ago
- #nonsteroidal MRAs
- #aldosterone synthase inhibitors
- #primary aldosteronism
- Medical therapy for primary aldosteronism has relied on mineralocorticoid receptor antagonists (MRAs) for decades.
- Current MRAs block downstream signaling of aldosterone but not its production, leading to reactive aldosterone elevation.
- Steroidal MRAs have limitations, including cross-reactivity with other nuclear receptors and hyperkalemia risks, especially in kidney insufficiency.
- Emerging therapies focus on suppressing aldosterone production, such as aldosterone synthase inhibitors.
- Nonsteroidal MRAs are also being explored as alternatives to traditional steroidal MRAs.
- The review discusses expected benefits and limitations of these new therapy classes.